Agrochemical giant Bayer has reached a proposed $7.25 billion settlement agreement to resolve thousands of U.S. lawsuits that allege the company's popular weedkiller Roundup causes cancer. The announcement was made on Tuesday, February 17, 2026, by Bayer and attorneys representing cancer patients, marking a significant development in the long-running legal battle.
Details of the Proposed Settlement
The proposed settlement was filed in St. Louis Circuit Court in Missouri, which is home to Bayer's North America crop science division and where many of the lawsuits have been brought. However, the settlement still requires formal court approval before it can be implemented. This move comes as Bayer continues to face mounting legal costs that the company warns threaten its ability to continue selling Roundup in U.S. agricultural markets.
Bayer's Position on Glyphosate Safety
Germany-based Bayer, which acquired Roundup maker Monsanto in 2018, maintains its dispute over the safety of glyphosate, the key ingredient in Roundup. The company specifically disputes assertions that glyphosate can cause non-Hodgkin's lymphoma, the cancer type cited in many of the lawsuits. Despite this position, Bayer CEO Bill Anderson stated on Tuesday that "litigation uncertainty has plagued the company for years, and this settlement gives the company a road to closure."
Supreme Court Considerations
The proposed settlement emerges as the U.S. Supreme Court prepares to hear arguments on Bayer's assertion that the U.S. Environmental Protection Agency's approval of Roundup without a cancer warning should invalidate claims filed in state courts. Importantly, this Supreme Court case would not be affected by the proposed settlement. However, the settlement would eliminate some of the risk from an eventual and uncertain Supreme Court ruling for both Bayer and patients seeking damages.
Legal and Market Implications
The settlement represents Bayer's strategic attempt to manage the substantial legal challenges that have accumulated since the Monsanto acquisition. While the company continues to dispute the cancer allegations, the financial burden of ongoing litigation has created significant pressure on its operations. The proposed $7.25 billion deal, if approved, would provide resolution for thousands of pending cases while allowing Bayer to maintain its position on product safety in regulatory discussions.
